Development of an eye treatment for ocular surface damage
| Biotech website | healometx.com |
| Investment details | £100,000 |
| Start date | October 2025 |
| Research area | Drug therapy |
| EB sub-type | Dystrophic EB, Junctional EB, EB Simplex |
| Aim | Symptom relief |
| Investment status | Current |
Investment summary
Healome Therapeutics is developing treatments for eye conditions. Its HealoTEAR formulation technology offers enhanced drug retention, lubrication and protection at the ocular surface, while being preservative free.
With increased time on eye, the eye drop could offer EB patients reduced frequency of dosing (currently, patients may need to use eye drops hourly), and longer term, it has the potential to be used as a drug delivery vehicle.
Investment from Cure EB, alongside others, will support further pre-clinical testing and a phase I clinical trial.